nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Vandetanib—thyroid cancer	0.222	0.41	CbGbCtD
Leflunomide—ABCG2—Sorafenib—thyroid cancer	0.134	0.247	CbGbCtD
Leflunomide—ABCG2—Doxorubicin—thyroid cancer	0.081	0.15	CbGbCtD
Leflunomide—CYP1A2—Sorafenib—thyroid cancer	0.0551	0.102	CbGbCtD
Leflunomide—CYP2C9—Sorafenib—thyroid cancer	0.0496	0.0917	CbGbCtD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00761	0.0801	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—NCOA4—thyroid cancer	0.00634	0.0668	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—OSMR—thyroid cancer	0.00603	0.0635	CbGpPWpGaD
Leflunomide—DHODH—thyroid gland—thyroid cancer	0.00467	0.137	CbGeAlD
Leflunomide—DHODH—head—thyroid cancer	0.00415	0.121	CbGeAlD
Leflunomide—AHR—saliva-secreting gland—thyroid cancer	0.00399	0.117	CbGeAlD
Leflunomide—PTK2B—Alpha4 beta1 integrin signaling events—PRKAR1A—thyroid cancer	0.00336	0.0355	CbGpPWpGaD
Leflunomide—AHR—trachea—thyroid cancer	0.00308	0.0901	CbGeAlD
Leflunomide—PTK2B—thyroid gland—thyroid cancer	0.00296	0.0867	CbGeAlD
Leflunomide—DHODH—lymph node—thyroid cancer	0.0029	0.085	CbGeAlD
Leflunomide—Niflumic Acid—PTGS2—thyroid cancer	0.00265	1	CrCbGaD
Leflunomide—PTK2B—head—thyroid cancer	0.00263	0.0769	CbGeAlD
Leflunomide—AHR—thyroid gland—thyroid cancer	0.00243	0.0713	CbGeAlD
Leflunomide—AHR—Circadian rythm related genes—NKX2-1—thyroid cancer	0.00228	0.024	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—NDUFA13—thyroid cancer	0.0022	0.0232	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—TPR—thyroid cancer	0.00185	0.0194	CbGpPWpGaD
Leflunomide—PTK2B—lymph node—thyroid cancer	0.00184	0.0539	CbGeAlD
Leflunomide—PTK2B—Interleukin-2 signaling—CDK1—thyroid cancer	0.00175	0.0184	CbGpPWpGaD
Leflunomide—ABCG2—saliva-secreting gland—thyroid cancer	0.00155	0.0453	CbGeAlD
Leflunomide—AHR—lymph node—thyroid cancer	0.00151	0.0443	CbGeAlD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.00149	0.0157	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—RXRA—thyroid cancer	0.00131	0.0138	CbGpPWpGaD
Leflunomide—ABCG2—Iron uptake and transport—CP—thyroid cancer	0.00129	0.0136	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—NRG1—thyroid cancer	0.00127	0.0134	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—EPO—thyroid cancer	0.00122	0.0128	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—MINPP1—thyroid cancer	0.00121	0.0128	CbGpPWpGaD
Leflunomide—PTK2B—IL-7 Signaling Pathway—CCND1—thyroid cancer	0.00121	0.0127	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.00116	0.0122	CbGpPWpGaD
Leflunomide—ABCG2—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.00111	0.0117	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—NDUFA13—thyroid cancer	0.00103	0.0109	CbGpPWpGaD
Leflunomide—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.001	0.0106	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000999	0.0105	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—HIF1A—thyroid cancer	0.000972	0.0102	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CHST14—thyroid cancer	0.000969	0.0102	CbGpPWpGaD
Leflunomide—ABCG2—thyroid gland—thyroid cancer	0.000944	0.0276	CbGeAlD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—HIF1A—thyroid cancer	0.000929	0.00978	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000913	0.00962	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—PTEN—thyroid cancer	0.00091	0.00959	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.000909	0.00958	CbGpPWpGaD
Leflunomide—CYP1A2—thyroid gland—thyroid cancer	0.000909	0.0266	CbGeAlD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—CDK1—thyroid cancer	0.000904	0.00953	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—CDK1—thyroid cancer	0.000897	0.00946	CbGpPWpGaD
Leflunomide—CYP1A2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000857	0.00903	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—CDK1—thyroid cancer	0.000853	0.00899	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000849	0.00895	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.000838	0.00883	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—PPARG—thyroid cancer	0.000826	0.00871	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—HPGD—thyroid cancer	0.000781	0.00823	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—thyroid cancer	0.000742	0.00782	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.000716	0.00755	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000714	0.00752	CbGpPWpGaD
Leflunomide—PTK2B—IL-7 Signaling Pathway—AKT1—thyroid cancer	0.00067	0.00706	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—NRAS—thyroid cancer	0.000626	0.0066	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—TPR—thyroid cancer	0.000618	0.00651	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—HRAS—thyroid cancer	0.000594	0.00626	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—CCND1—thyroid cancer	0.00059	0.00622	CbGpPWpGaD
Leflunomide—ABCG2—lymph node—thyroid cancer	0.000586	0.0172	CbGeAlD
Leflunomide—AHR—Circadian rythm related genes—PPARG—thyroid cancer	0.000583	0.00614	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—NRAS—thyroid cancer	0.00056	0.00591	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—KRAS—thyroid cancer	0.000539	0.00568	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000521	0.00549	CbGpPWpGaD
Leflunomide—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000518	0.00545	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000503	0.0053	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—HRAS—thyroid cancer	0.000501	0.00528	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—KRAS—thyroid cancer	0.000482	0.00508	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—HRAS—thyroid cancer	0.000458	0.00483	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.000457	0.00481	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—TPR—thyroid cancer	0.000449	0.00473	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000446	0.0047	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—AKT1—thyroid cancer	0.000443	0.00466	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PRKAR1A—thyroid cancer	0.000441	0.00465	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000426	0.00449	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—CDK1—thyroid cancer	0.000419	0.00441	CbGpPWpGaD
Leflunomide—Mouth ulceration—Doxorubicin—thyroid cancer	0.000417	0.00127	CcSEcCtD
Leflunomide—Neoplasm—Doxorubicin—thyroid cancer	0.000417	0.00127	CcSEcCtD
Leflunomide—Ecchymosis—Doxorubicin—thyroid cancer	0.000417	0.00127	CcSEcCtD
Leflunomide—Bladder pain—Doxorubicin—thyroid cancer	0.000417	0.00127	CcSEcCtD
Leflunomide—Diabetes mellitus—Epirubicin—thyroid cancer	0.000416	0.00127	CcSEcCtD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—KRAS—thyroid cancer	0.000416	0.00438	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000416	0.00127	CcSEcCtD
Leflunomide—Fatigue—Sorafenib—thyroid cancer	0.000415	0.00127	CcSEcCtD
Leflunomide—Constipation—Sorafenib—thyroid cancer	0.000412	0.00126	CcSEcCtD
Leflunomide—Pain—Sorafenib—thyroid cancer	0.000412	0.00126	CcSEcCtD
Leflunomide—PTK2B—IL2-mediated signaling events—HRAS—thyroid cancer	0.00041	0.00432	CbGpPWpGaD
Leflunomide—Eczema—Epirubicin—thyroid cancer	0.000403	0.00123	CcSEcCtD
Leflunomide—Hepatic failure—Epirubicin—thyroid cancer	0.000403	0.00123	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IFNA2—thyroid cancer	0.000403	0.00424	CbGpPWpGaD
Leflunomide—Sepsis—Doxorubicin—thyroid cancer	0.000401	0.00122	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—PTEN—thyroid cancer	0.0004	0.00421	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000394	0.0012	CcSEcCtD
Leflunomide—Lymphadenopathy—Doxorubicin—thyroid cancer	0.000393	0.0012	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—CHST14—thyroid cancer	0.00039	0.00411	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000386	0.00407	CbGpPWpGaD
Leflunomide—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000385	0.00118	CcSEcCtD
Leflunomide—Urticaria—Sorafenib—thyroid cancer	0.000383	0.00117	CcSEcCtD
Leflunomide—Abdominal pain—Sorafenib—thyroid cancer	0.000381	0.00116	CcSEcCtD
Leflunomide—Body temperature increased—Sorafenib—thyroid cancer	0.000381	0.00116	CcSEcCtD
Leflunomide—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000374	0.00114	CcSEcCtD
Leflunomide—Hepatic failure—Doxorubicin—thyroid cancer	0.000373	0.00114	CcSEcCtD
Leflunomide—Eczema—Doxorubicin—thyroid cancer	0.000373	0.00114	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—BRAF—thyroid cancer	0.00037	0.0039	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—TP53—thyroid cancer	0.00037	0.0039	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—thyroid cancer	0.000368	0.00387	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—HRAS—thyroid cancer	0.000362	0.00382	CbGpPWpGaD
Leflunomide—Osteoarthritis—Epirubicin—thyroid cancer	0.000362	0.00111	CcSEcCtD
Leflunomide—PTK2B—FGF signaling pathway—AKT1—thyroid cancer	0.000362	0.00382	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—HRAS—thyroid cancer	0.000358	0.00377	CbGpPWpGaD
Leflunomide—Migraine—Epirubicin—thyroid cancer	0.000356	0.00109	CcSEcCtD
Leflunomide—Hypersensitivity—Sorafenib—thyroid cancer	0.000355	0.00108	CcSEcCtD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—HRAS—thyroid cancer	0.000354	0.00373	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—RAP1GAP—thyroid cancer	0.000351	0.0037	CbGpPWpGaD
Leflunomide—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000346	0.00106	CcSEcCtD
Leflunomide—Asthenia—Sorafenib—thyroid cancer	0.000346	0.00106	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000343	0.00362	CbGpPWpGaD
Leflunomide—Pruritus—Sorafenib—thyroid cancer	0.000341	0.00104	CcSEcCtD
Leflunomide—DHODH—Metabolism—SLC5A5—thyroid cancer	0.000336	0.00354	CbGpPWpGaD
Leflunomide—Osteoarthritis—Doxorubicin—thyroid cancer	0.000335	0.00102	CcSEcCtD
Leflunomide—Liver function test abnormal—Epirubicin—thyroid cancer	0.000334	0.00102	CcSEcCtD
Leflunomide—Dry skin—Epirubicin—thyroid cancer	0.000332	0.00101	CcSEcCtD
Leflunomide—Migraine—Doxorubicin—thyroid cancer	0.00033	0.00101	CcSEcCtD
Leflunomide—Hypokalaemia—Epirubicin—thyroid cancer	0.00033	0.00101	CcSEcCtD
Leflunomide—Diarrhoea—Sorafenib—thyroid cancer	0.000329	0.00101	CcSEcCtD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—AKT1—thyroid cancer	0.000328	0.00346	CbGpPWpGaD
Leflunomide—Breast disorder—Epirubicin—thyroid cancer	0.000327	0.000999	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000326	0.000996	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—NRAS—thyroid cancer	0.000324	0.00342	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—NRAS—thyroid cancer	0.000322	0.00339	CbGpPWpGaD
Leflunomide—Gastritis—Epirubicin—thyroid cancer	0.00032	0.000979	CcSEcCtD
Leflunomide—PTK2B—Integrins in angiogenesis—AKT1—thyroid cancer	0.00032	0.00337	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—AKT1—thyroid cancer	0.00032	0.00337	CbGpPWpGaD
Leflunomide—Dizziness—Sorafenib—thyroid cancer	0.000318	0.000973	CcSEcCtD
Leflunomide—PTK2B—LPA receptor mediated events—AKT1—thyroid cancer	0.000316	0.00333	CbGpPWpGaD
Leflunomide—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000313	0.0033	CbGpPWpGaD
Leflunomide—Asthma—Epirubicin—thyroid cancer	0.000313	0.000956	CcSEcCtD
Leflunomide—Influenza—Epirubicin—thyroid cancer	0.000313	0.000956	CcSEcCtD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—AKT1—thyroid cancer	0.000312	0.00329	CbGpPWpGaD
Leflunomide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000311	0.00328	CbGpPWpGaD
Leflunomide—Eosinophilia—Epirubicin—thyroid cancer	0.00031	0.000946	CcSEcCtD
Leflunomide—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000309	0.000945	CcSEcCtD
Leflunomide—Dry skin—Doxorubicin—thyroid cancer	0.000307	0.000938	CcSEcCtD
Leflunomide—Pancreatitis—Epirubicin—thyroid cancer	0.000307	0.000937	CcSEcCtD
Leflunomide—Vomiting—Sorafenib—thyroid cancer	0.000306	0.000935	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—NRAS—thyroid cancer	0.000306	0.00323	CbGpPWpGaD
Leflunomide—Hypokalaemia—Doxorubicin—thyroid cancer	0.000305	0.000931	CcSEcCtD
Leflunomide—Angina pectoris—Epirubicin—thyroid cancer	0.000305	0.000931	CcSEcCtD
Leflunomide—Rash—Sorafenib—thyroid cancer	0.000304	0.000927	CcSEcCtD
Leflunomide—Dermatitis—Sorafenib—thyroid cancer	0.000303	0.000926	CcSEcCtD
Leflunomide—Breast disorder—Doxorubicin—thyroid cancer	0.000303	0.000925	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000302	0.000921	CcSEcCtD
Leflunomide—Headache—Sorafenib—thyroid cancer	0.000302	0.000921	CcSEcCtD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—thyroid cancer	0.000301	0.00317	CbGpPWpGaD
Leflunomide—Bronchitis—Epirubicin—thyroid cancer	0.000301	0.000919	CcSEcCtD
Leflunomide—Pancytopenia—Epirubicin—thyroid cancer	0.000297	0.000908	CcSEcCtD
Leflunomide—Gastritis—Doxorubicin—thyroid cancer	0.000297	0.000906	CcSEcCtD
Leflunomide—ABCG2—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000296	0.00311	CbGpPWpGaD
Leflunomide—Dysuria—Epirubicin—thyroid cancer	0.000293	0.000894	CcSEcCtD
Leflunomide—Neutropenia—Epirubicin—thyroid cancer	0.000293	0.000894	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000291	0.000888	CcSEcCtD
Leflunomide—AHR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.00029	0.00305	CbGpPWpGaD
Leflunomide—Influenza—Doxorubicin—thyroid cancer	0.00029	0.000884	CcSEcCtD
Leflunomide—Asthma—Doxorubicin—thyroid cancer	0.00029	0.000884	CcSEcCtD
Leflunomide—Pollakiuria—Epirubicin—thyroid cancer	0.000289	0.000883	CcSEcCtD
Leflunomide—Eosinophilia—Doxorubicin—thyroid cancer	0.000287	0.000876	CcSEcCtD
Leflunomide—Nausea—Sorafenib—thyroid cancer	0.000286	0.000874	CcSEcCtD
Leflunomide—Pancreatitis—Doxorubicin—thyroid cancer	0.000284	0.000867	CcSEcCtD
Leflunomide—Weight decreased—Epirubicin—thyroid cancer	0.000283	0.000865	CcSEcCtD
Leflunomide—Hyperglycaemia—Epirubicin—thyroid cancer	0.000282	0.000862	CcSEcCtD
Leflunomide—DHODH—Metabolism—RXRA—thyroid cancer	0.000282	0.00297	CbGpPWpGaD
Leflunomide—Angina pectoris—Doxorubicin—thyroid cancer	0.000282	0.000861	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—CALCB—thyroid cancer	0.000282	0.00297	CbGpPWpGaD
Leflunomide—Pneumonia—Epirubicin—thyroid cancer	0.000281	0.000857	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—KRAS—thyroid cancer	0.000279	0.00294	CbGpPWpGaD
Leflunomide—Infestation NOS—Epirubicin—thyroid cancer	0.000279	0.000852	CcSEcCtD
Leflunomide—Infestation—Epirubicin—thyroid cancer	0.000279	0.000852	CcSEcCtD
Leflunomide—Bronchitis—Doxorubicin—thyroid cancer	0.000278	0.00085	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—KRAS—thyroid cancer	0.000277	0.00292	CbGpPWpGaD
Leflunomide—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000277	0.000845	CcSEcCtD
Leflunomide—Pancytopenia—Doxorubicin—thyroid cancer	0.000275	0.00084	CcSEcCtD
Leflunomide—Renal failure—Epirubicin—thyroid cancer	0.000274	0.000838	CcSEcCtD
Leflunomide—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000274	0.000835	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—TP53—thyroid cancer	0.000273	0.00288	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—HRAS—thyroid cancer	0.000272	0.00287	CbGpPWpGaD
Leflunomide—Stomatitis—Epirubicin—thyroid cancer	0.000272	0.000831	CcSEcCtD
Leflunomide—Jaundice—Epirubicin—thyroid cancer	0.000272	0.000831	CcSEcCtD
Leflunomide—Conjunctivitis—Epirubicin—thyroid cancer	0.000271	0.000828	CcSEcCtD
Leflunomide—Urinary tract infection—Epirubicin—thyroid cancer	0.000271	0.000828	CcSEcCtD
Leflunomide—Dysuria—Doxorubicin—thyroid cancer	0.000271	0.000827	CcSEcCtD
Leflunomide—Neutropenia—Doxorubicin—thyroid cancer	0.000271	0.000827	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000269	0.000822	CcSEcCtD
Leflunomide—Pollakiuria—Doxorubicin—thyroid cancer	0.000268	0.000817	CcSEcCtD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000267	0.00282	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TRIM33—thyroid cancer	0.000267	0.00282	CbGpPWpGaD
Leflunomide—Haematuria—Epirubicin—thyroid cancer	0.000266	0.000813	CcSEcCtD
Leflunomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000266	0.0028	CbGpPWpGaD
Leflunomide—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000264	0.000806	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—KRAS—thyroid cancer	0.000263	0.00278	CbGpPWpGaD
Leflunomide—Epistaxis—Epirubicin—thyroid cancer	0.000263	0.000804	CcSEcCtD
Leflunomide—Weight decreased—Doxorubicin—thyroid cancer	0.000262	0.0008	CcSEcCtD
Leflunomide—Sinusitis—Epirubicin—thyroid cancer	0.000262	0.0008	CcSEcCtD
Leflunomide—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000261	0.000798	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—PTEN—thyroid cancer	0.000261	0.00275	CbGpPWpGaD
Leflunomide—Agranulocytosis—Epirubicin—thyroid cancer	0.00026	0.000795	CcSEcCtD
Leflunomide—Pneumonia—Doxorubicin—thyroid cancer	0.00026	0.000793	CcSEcCtD
Leflunomide—Infestation NOS—Doxorubicin—thyroid cancer	0.000258	0.000789	CcSEcCtD
Leflunomide—Infestation—Doxorubicin—thyroid cancer	0.000258	0.000789	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000256	0.000782	CcSEcCtD
Leflunomide—PTK2B—CXCR4-mediated signaling events—AKT1—thyroid cancer	0.000254	0.00268	CbGpPWpGaD
Leflunomide—Renal failure—Doxorubicin—thyroid cancer	0.000254	0.000775	CcSEcCtD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000254	0.00267	CbGpPWpGaD
Leflunomide—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000253	0.000773	CcSEcCtD
Leflunomide—Haemoglobin—Epirubicin—thyroid cancer	0.000252	0.000769	CcSEcCtD
Leflunomide—Jaundice—Doxorubicin—thyroid cancer	0.000252	0.000769	CcSEcCtD
Leflunomide—Stomatitis—Doxorubicin—thyroid cancer	0.000252	0.000769	CcSEcCtD
Leflunomide—Rhinitis—Epirubicin—thyroid cancer	0.000251	0.000767	CcSEcCtD
Leflunomide—Urinary tract infection—Doxorubicin—thyroid cancer	0.000251	0.000766	CcSEcCtD
Leflunomide—Conjunctivitis—Doxorubicin—thyroid cancer	0.000251	0.000766	CcSEcCtD
Leflunomide—Haemorrhage—Epirubicin—thyroid cancer	0.000251	0.000765	CcSEcCtD
Leflunomide—Hepatitis—Epirubicin—thyroid cancer	0.000251	0.000765	CcSEcCtD
Leflunomide—Pharyngitis—Epirubicin—thyroid cancer	0.000249	0.000759	CcSEcCtD
Leflunomide—Urinary tract disorder—Epirubicin—thyroid cancer	0.000247	0.000755	CcSEcCtD
Leflunomide—Oedema peripheral—Epirubicin—thyroid cancer	0.000247	0.000754	CcSEcCtD
Leflunomide—Haematuria—Doxorubicin—thyroid cancer	0.000246	0.000752	CcSEcCtD
Leflunomide—Connective tissue disorder—Epirubicin—thyroid cancer	0.000246	0.000752	CcSEcCtD
Leflunomide—Urethral disorder—Epirubicin—thyroid cancer	0.000246	0.00075	CcSEcCtD
Leflunomide—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000244	0.000746	CcSEcCtD
Leflunomide—Epistaxis—Doxorubicin—thyroid cancer	0.000244	0.000744	CcSEcCtD
Leflunomide—Sinusitis—Doxorubicin—thyroid cancer	0.000242	0.00074	CcSEcCtD
Leflunomide—Agranulocytosis—Doxorubicin—thyroid cancer	0.000241	0.000736	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—AKT1—thyroid cancer	0.000241	0.00254	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—HRAS—thyroid cancer	0.000237	0.0025	CbGpPWpGaD
Leflunomide—Erythema multiforme—Epirubicin—thyroid cancer	0.000237	0.000723	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—HRAS—thyroid cancer	0.000236	0.00248	CbGpPWpGaD
Leflunomide—Eye disorder—Epirubicin—thyroid cancer	0.000234	0.000715	CcSEcCtD
Leflunomide—Haemoglobin—Doxorubicin—thyroid cancer	0.000233	0.000711	CcSEcCtD
Leflunomide—Cardiac disorder—Epirubicin—thyroid cancer	0.000232	0.00071	CcSEcCtD
Leflunomide—Rhinitis—Doxorubicin—thyroid cancer	0.000232	0.00071	CcSEcCtD
Leflunomide—Haemorrhage—Doxorubicin—thyroid cancer	0.000232	0.000708	CcSEcCtD
Leflunomide—Hepatitis—Doxorubicin—thyroid cancer	0.000232	0.000708	CcSEcCtD
Leflunomide—Pharyngitis—Doxorubicin—thyroid cancer	0.00023	0.000703	CcSEcCtD
Leflunomide—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000229	0.000699	CcSEcCtD
Leflunomide—Oedema peripheral—Doxorubicin—thyroid cancer	0.000228	0.000697	CcSEcCtD
Leflunomide—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000228	0.000696	CcSEcCtD
Leflunomide—Urethral disorder—Doxorubicin—thyroid cancer	0.000227	0.000694	CcSEcCtD
Leflunomide—Immune system disorder—Epirubicin—thyroid cancer	0.000226	0.000691	CcSEcCtD
Leflunomide—Mediastinal disorder—Epirubicin—thyroid cancer	0.000226	0.000689	CcSEcCtD
Leflunomide—Chills—Epirubicin—thyroid cancer	0.000225	0.000686	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—HRAS—thyroid cancer	0.000224	0.00236	CbGpPWpGaD
Leflunomide—Arrhythmia—Epirubicin—thyroid cancer	0.000224	0.000683	CcSEcCtD
Leflunomide—Alopecia—Epirubicin—thyroid cancer	0.000221	0.000676	CcSEcCtD
Leflunomide—Mental disorder—Epirubicin—thyroid cancer	0.000219	0.00067	CcSEcCtD
Leflunomide—Erythema multiforme—Doxorubicin—thyroid cancer	0.000219	0.000669	CcSEcCtD
Leflunomide—Malnutrition—Epirubicin—thyroid cancer	0.000218	0.000666	CcSEcCtD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000217	0.00229	CbGpPWpGaD
Leflunomide—Eye disorder—Doxorubicin—thyroid cancer	0.000217	0.000662	CcSEcCtD
Leflunomide—Cardiac disorder—Doxorubicin—thyroid cancer	0.000215	0.000657	CcSEcCtD
Leflunomide—Flatulence—Epirubicin—thyroid cancer	0.000215	0.000656	CcSEcCtD
Leflunomide—Dysgeusia—Epirubicin—thyroid cancer	0.000214	0.000652	CcSEcCtD
Leflunomide—Back pain—Epirubicin—thyroid cancer	0.000211	0.000644	CcSEcCtD
Leflunomide—Muscle spasms—Epirubicin—thyroid cancer	0.00021	0.00064	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—AKT1—thyroid cancer	0.000209	0.00221	CbGpPWpGaD
Leflunomide—Immune system disorder—Doxorubicin—thyroid cancer	0.000209	0.000639	CcSEcCtD
Leflunomide—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000209	0.000638	CcSEcCtD
Leflunomide—Chills—Doxorubicin—thyroid cancer	0.000208	0.000635	CcSEcCtD
Leflunomide—Arrhythmia—Doxorubicin—thyroid cancer	0.000207	0.000632	CcSEcCtD
Leflunomide—Vision blurred—Epirubicin—thyroid cancer	0.000206	0.000628	CcSEcCtD
Leflunomide—Alopecia—Doxorubicin—thyroid cancer	0.000205	0.000626	CcSEcCtD
Leflunomide—Mental disorder—Doxorubicin—thyroid cancer	0.000203	0.00062	CcSEcCtD
Leflunomide—Ill-defined disorder—Epirubicin—thyroid cancer	0.000202	0.000618	CcSEcCtD
Leflunomide—PTK2B—Immune System—TPR—thyroid cancer	0.000202	0.00213	CbGpPWpGaD
Leflunomide—Malnutrition—Doxorubicin—thyroid cancer	0.000202	0.000616	CcSEcCtD
Leflunomide—Anaemia—Epirubicin—thyroid cancer	0.000202	0.000616	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—KRAS—thyroid cancer	0.0002	0.00211	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—LGALS3—thyroid cancer	0.0002	0.00211	CbGpPWpGaD
Leflunomide—Flatulence—Doxorubicin—thyroid cancer	0.000199	0.000607	CcSEcCtD
Leflunomide—PTK2B—Immune System—PRKAR1A—thyroid cancer	0.000199	0.00209	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—AKT1—thyroid cancer	0.000198	0.00208	CbGpPWpGaD
Leflunomide—Dysgeusia—Doxorubicin—thyroid cancer	0.000198	0.000603	CcSEcCtD
Leflunomide—Malaise—Epirubicin—thyroid cancer	0.000197	0.000601	CcSEcCtD
Leflunomide—ABCG2—Metabolism—MINPP1—thyroid cancer	0.000196	0.00207	CbGpPWpGaD
Leflunomide—Vertigo—Epirubicin—thyroid cancer	0.000196	0.000598	CcSEcCtD
Leflunomide—Leukopenia—Epirubicin—thyroid cancer	0.000195	0.000596	CcSEcCtD
Leflunomide—Back pain—Doxorubicin—thyroid cancer	0.000195	0.000596	CcSEcCtD
Leflunomide—Muscle spasms—Doxorubicin—thyroid cancer	0.000194	0.000592	CcSEcCtD
Leflunomide—Palpitations—Epirubicin—thyroid cancer	0.000193	0.000589	CcSEcCtD
Leflunomide—Cough—Epirubicin—thyroid cancer	0.00019	0.000581	CcSEcCtD
Leflunomide—Vision blurred—Doxorubicin—thyroid cancer	0.00019	0.000581	CcSEcCtD
Leflunomide—Hypertension—Epirubicin—thyroid cancer	0.000188	0.000575	CcSEcCtD
Leflunomide—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000187	0.000572	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—HRAS—thyroid cancer	0.000187	0.00197	CbGpPWpGaD
Leflunomide—Anaemia—Doxorubicin—thyroid cancer	0.000186	0.00057	CcSEcCtD
Leflunomide—Arthralgia—Epirubicin—thyroid cancer	0.000186	0.000567	CcSEcCtD
Leflunomide—Chest pain—Epirubicin—thyroid cancer	0.000186	0.000567	CcSEcCtD
Leflunomide—Myalgia—Epirubicin—thyroid cancer	0.000186	0.000567	CcSEcCtD
Leflunomide—Anxiety—Epirubicin—thyroid cancer	0.000185	0.000565	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000184	0.000563	CcSEcCtD
Leflunomide—Discomfort—Epirubicin—thyroid cancer	0.000183	0.00056	CcSEcCtD
Leflunomide—Malaise—Doxorubicin—thyroid cancer	0.000182	0.000556	CcSEcCtD
Leflunomide—Dry mouth—Epirubicin—thyroid cancer	0.000182	0.000554	CcSEcCtD
Leflunomide—Vertigo—Doxorubicin—thyroid cancer	0.000181	0.000554	CcSEcCtD
Leflunomide—Leukopenia—Doxorubicin—thyroid cancer	0.000181	0.000552	CcSEcCtD
Leflunomide—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.00018	0.0019	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TCF7L1—thyroid cancer	0.000178	0.00188	CbGpPWpGaD
Leflunomide—Palpitations—Doxorubicin—thyroid cancer	0.000178	0.000545	CcSEcCtD
Leflunomide—DHODH—Metabolism—PPARG—thyroid cancer	0.000178	0.00188	CbGpPWpGaD
Leflunomide—Anaphylactic shock—Epirubicin—thyroid cancer	0.000178	0.000544	CcSEcCtD
Leflunomide—Infection—Epirubicin—thyroid cancer	0.000177	0.00054	CcSEcCtD
Leflunomide—Cough—Doxorubicin—thyroid cancer	0.000176	0.000538	CcSEcCtD
Leflunomide—Nervous system disorder—Epirubicin—thyroid cancer	0.000175	0.000533	CcSEcCtD
Leflunomide—Thrombocytopenia—Epirubicin—thyroid cancer	0.000174	0.000532	CcSEcCtD
Leflunomide—Hypertension—Doxorubicin—thyroid cancer	0.000174	0.000532	CcSEcCtD
Leflunomide—Tachycardia—Epirubicin—thyroid cancer	0.000174	0.00053	CcSEcCtD
Leflunomide—Skin disorder—Epirubicin—thyroid cancer	0.000173	0.000528	CcSEcCtD
Leflunomide—Hyperhidrosis—Epirubicin—thyroid cancer	0.000172	0.000525	CcSEcCtD
Leflunomide—Chest pain—Doxorubicin—thyroid cancer	0.000172	0.000525	CcSEcCtD
Leflunomide—Arthralgia—Doxorubicin—thyroid cancer	0.000172	0.000525	CcSEcCtD
Leflunomide—Myalgia—Doxorubicin—thyroid cancer	0.000172	0.000525	CcSEcCtD
Leflunomide—Anxiety—Doxorubicin—thyroid cancer	0.000171	0.000523	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000171	0.000521	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—HRAS—thyroid cancer	0.00017	0.00179	CbGpPWpGaD
Leflunomide—Discomfort—Doxorubicin—thyroid cancer	0.00017	0.000518	CcSEcCtD
Leflunomide—Anorexia—Epirubicin—thyroid cancer	0.00017	0.000518	CcSEcCtD
Leflunomide—Dry mouth—Doxorubicin—thyroid cancer	0.000168	0.000513	CcSEcCtD
Leflunomide—ABCG2—Metabolism—NDUFA13—thyroid cancer	0.000167	0.00176	CbGpPWpGaD
Leflunomide—Hypotension—Epirubicin—thyroid cancer	0.000166	0.000508	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—AKT1—thyroid cancer	0.000165	0.00174	CbGpPWpGaD
Leflunomide—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000165	0.000503	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000164	0.00173	CbGpPWpGaD
Leflunomide—Infection—Doxorubicin—thyroid cancer	0.000164	0.0005	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000162	0.000495	CcSEcCtD
Leflunomide—Nervous system disorder—Doxorubicin—thyroid cancer	0.000161	0.000493	CcSEcCtD
Leflunomide—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000161	0.000492	CcSEcCtD
Leflunomide—Insomnia—Epirubicin—thyroid cancer	0.000161	0.000492	CcSEcCtD
Leflunomide—Tachycardia—Doxorubicin—thyroid cancer	0.000161	0.000491	CcSEcCtD
Leflunomide—Skin disorder—Doxorubicin—thyroid cancer	0.00016	0.000488	CcSEcCtD
Leflunomide—Paraesthesia—Epirubicin—thyroid cancer	0.00016	0.000488	CcSEcCtD
Leflunomide—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000159	0.000486	CcSEcCtD
Leflunomide—Dyspnoea—Epirubicin—thyroid cancer	0.000159	0.000485	CcSEcCtD
Leflunomide—Anorexia—Doxorubicin—thyroid cancer	0.000157	0.000479	CcSEcCtD
Leflunomide—ABCG2—Metabolism—CHST14—thyroid cancer	0.000157	0.00165	CbGpPWpGaD
Leflunomide—Dyspepsia—Epirubicin—thyroid cancer	0.000157	0.000478	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—CP—thyroid cancer	0.000155	0.00163	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000155	0.00163	CbGpPWpGaD
Leflunomide—Decreased appetite—Epirubicin—thyroid cancer	0.000155	0.000472	CcSEcCtD
Leflunomide—Hypotension—Doxorubicin—thyroid cancer	0.000154	0.00047	CcSEcCtD
Leflunomide—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000154	0.00162	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000154	0.000469	CcSEcCtD
Leflunomide—Fatigue—Epirubicin—thyroid cancer	0.000153	0.000469	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000152	0.00161	CbGpPWpGaD
Leflunomide—Constipation—Epirubicin—thyroid cancer	0.000152	0.000465	CcSEcCtD
Leflunomide—Pain—Epirubicin—thyroid cancer	0.000152	0.000465	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—AKT1—thyroid cancer	0.00015	0.00158	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—NRAS—thyroid cancer	0.00015	0.00158	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00015	0.000458	CcSEcCtD
Leflunomide—Insomnia—Doxorubicin—thyroid cancer	0.000149	0.000455	CcSEcCtD
Leflunomide—Paraesthesia—Doxorubicin—thyroid cancer	0.000148	0.000452	CcSEcCtD
Leflunomide—Dyspnoea—Doxorubicin—thyroid cancer	0.000147	0.000448	CcSEcCtD
Leflunomide—Feeling abnormal—Epirubicin—thyroid cancer	0.000147	0.000448	CcSEcCtD
Leflunomide—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000146	0.000444	CcSEcCtD
Leflunomide—Dyspepsia—Doxorubicin—thyroid cancer	0.000145	0.000443	CcSEcCtD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	0.000143	0.00151	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000143	0.00151	CbGpPWpGaD
Leflunomide—Decreased appetite—Doxorubicin—thyroid cancer	0.000143	0.000437	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000142	0.000434	CcSEcCtD
Leflunomide—Fatigue—Doxorubicin—thyroid cancer	0.000142	0.000434	CcSEcCtD
Leflunomide—Urticaria—Epirubicin—thyroid cancer	0.000141	0.000432	CcSEcCtD
Leflunomide—Pain—Doxorubicin—thyroid cancer	0.000141	0.00043	CcSEcCtD
Leflunomide—Constipation—Doxorubicin—thyroid cancer	0.000141	0.00043	CcSEcCtD
Leflunomide—Abdominal pain—Epirubicin—thyroid cancer	0.000141	0.00043	CcSEcCtD
Leflunomide—Body temperature increased—Epirubicin—thyroid cancer	0.000141	0.00043	CcSEcCtD
Leflunomide—DHODH—Metabolism—PTGS2—thyroid cancer	0.00014	0.00148	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDK1—thyroid cancer	0.000137	0.00144	CbGpPWpGaD
Leflunomide—Feeling abnormal—Doxorubicin—thyroid cancer	0.000136	0.000414	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—RXRA—thyroid cancer	0.000135	0.00142	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000135	0.000411	CcSEcCtD
Leflunomide—PTK2B—Immune System—IFNA2—thyroid cancer	0.000132	0.00139	CbGpPWpGaD
Leflunomide—Hypersensitivity—Epirubicin—thyroid cancer	0.000131	0.0004	CcSEcCtD
Leflunomide—Urticaria—Doxorubicin—thyroid cancer	0.000131	0.0004	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—TSHR—thyroid cancer	0.000131	0.00138	CbGpPWpGaD
Leflunomide—Abdominal pain—Doxorubicin—thyroid cancer	0.00013	0.000398	CcSEcCtD
Leflunomide—Body temperature increased—Doxorubicin—thyroid cancer	0.00013	0.000398	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—KRAS—thyroid cancer	0.000129	0.00136	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PRKAR1A—thyroid cancer	0.000128	0.00135	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000128	0.00135	CbGpPWpGaD
Leflunomide—Asthenia—Epirubicin—thyroid cancer	0.000128	0.00039	CcSEcCtD
Leflunomide—ABCG2—Metabolism—HPGD—thyroid cancer	0.000126	0.00133	CbGpPWpGaD
Leflunomide—Pruritus—Epirubicin—thyroid cancer	0.000126	0.000385	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—MEN1—thyroid cancer	0.000123	0.00129	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000122	0.00129	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PTEN—thyroid cancer	0.000122	0.00129	CbGpPWpGaD
Leflunomide—Diarrhoea—Epirubicin—thyroid cancer	0.000122	0.000372	CcSEcCtD
Leflunomide—Hypersensitivity—Doxorubicin—thyroid cancer	0.000121	0.000371	CcSEcCtD
Leflunomide—Asthenia—Doxorubicin—thyroid cancer	0.000118	0.000361	CcSEcCtD
Leflunomide—Dizziness—Epirubicin—thyroid cancer	0.000118	0.000359	CcSEcCtD
Leflunomide—Pruritus—Doxorubicin—thyroid cancer	0.000117	0.000356	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000116	0.00122	CbGpPWpGaD
Leflunomide—CYP1A2—Biological oxidations—RXRA—thyroid cancer	0.000115	0.00121	CbGpPWpGaD
Leflunomide—Vomiting—Epirubicin—thyroid cancer	0.000113	0.000346	CcSEcCtD
Leflunomide—Diarrhoea—Doxorubicin—thyroid cancer	0.000113	0.000344	CcSEcCtD
Leflunomide—Rash—Epirubicin—thyroid cancer	0.000112	0.000343	CcSEcCtD
Leflunomide—Dermatitis—Epirubicin—thyroid cancer	0.000112	0.000342	CcSEcCtD
Leflunomide—Headache—Epirubicin—thyroid cancer	0.000111	0.00034	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—PTCH1—thyroid cancer	0.000111	0.00117	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.00011	0.00116	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HRAS—thyroid cancer	0.00011	0.00116	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NRG1—thyroid cancer	0.00011	0.00116	CbGpPWpGaD
Leflunomide—Dizziness—Doxorubicin—thyroid cancer	0.000109	0.000333	CcSEcCtD
Leflunomide—Nausea—Epirubicin—thyroid cancer	0.000106	0.000323	CcSEcCtD
Leflunomide—Vomiting—Doxorubicin—thyroid cancer	0.000105	0.00032	CcSEcCtD
Leflunomide—Rash—Doxorubicin—thyroid cancer	0.000104	0.000317	CcSEcCtD
Leflunomide—Dermatitis—Doxorubicin—thyroid cancer	0.000104	0.000317	CcSEcCtD
Leflunomide—Headache—Doxorubicin—thyroid cancer	0.000103	0.000315	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—SST—thyroid cancer	0.000101	0.00107	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—MINPP1—thyroid cancer	9.9e-05	0.00104	CbGpPWpGaD
Leflunomide—Nausea—Doxorubicin—thyroid cancer	9.78e-05	0.000299	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—CALCA—thyroid cancer	9.77e-05	0.00103	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—RXRA—thyroid cancer	9.74e-05	0.00103	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	9.35e-05	0.000986	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDK1—thyroid cancer	8.84e-05	0.000932	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—MINPP1—thyroid cancer	8.46e-05	0.000892	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NDUFA13—thyroid cancer	8.42e-05	0.000887	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CHST14—thyroid cancer	7.92e-05	0.000834	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—TPR—thyroid cancer	7.26e-05	0.000765	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NDUFA13—thyroid cancer	7.2e-05	0.000758	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PRKAR1A—thyroid cancer	7.14e-05	0.000752	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NRG1—thyroid cancer	7.1e-05	0.000748	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—AKT1—thyroid cancer	7.04e-05	0.000742	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CHST14—thyroid cancer	6.77e-05	0.000713	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HPGD—thyroid cancer	6.38e-05	0.000672	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TERT—thyroid cancer	6.37e-05	0.000672	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HIF1A—thyroid cancer	6.1e-05	0.000642	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PTEN—thyroid cancer	5.5e-05	0.00058	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HPGD—thyroid cancer	5.45e-05	0.000575	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC5A5—thyroid cancer	5.43e-05	0.000572	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.18e-05	0.000545	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—BRAF—thyroid cancer	5.05e-05	0.000532	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NRAS—thyroid cancer	4.91e-05	0.000517	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—RXRA—thyroid cancer	4.56e-05	0.000481	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.42e-05	0.000466	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KRAS—thyroid cancer	4.22e-05	0.000445	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCND1—thyroid cancer	3.68e-05	0.000388	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TPR—thyroid cancer	3.67e-05	0.000386	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	3.61e-05	0.00038	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HRAS—thyroid cancer	3.59e-05	0.000378	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTEN—thyroid cancer	3.56e-05	0.000375	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.27e-05	0.000344	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NRAS—thyroid cancer	3.17e-05	0.000334	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AKT1—thyroid cancer	3.17e-05	0.000334	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TPR—thyroid cancer	3.13e-05	0.00033	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	3.08e-05	0.000325	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPARG—thyroid cancer	2.88e-05	0.000304	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.79e-05	0.000294	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC5A5—thyroid cancer	2.74e-05	0.000289	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KRAS—thyroid cancer	2.73e-05	0.000288	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.57e-05	0.000271	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—thyroid cancer	2.43e-05	0.000256	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC5A5—thyroid cancer	2.34e-05	0.000247	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HRAS—thyroid cancer	2.32e-05	0.000245	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—RXRA—thyroid cancer	2.31e-05	0.000243	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTGS2—thyroid cancer	2.27e-05	0.000239	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.24e-05	0.000236	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.2e-05	0.000232	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT1—thyroid cancer	2.05e-05	0.000216	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTEN—thyroid cancer	1.98e-05	0.000208	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—RXRA—thyroid cancer	1.97e-05	0.000208	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.92e-05	0.000202	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PPARG—thyroid cancer	1.46e-05	0.000153	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PPARG—thyroid cancer	1.24e-05	0.000131	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTGS2—thyroid cancer	1.14e-05	0.000121	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKT1—thyroid cancer	1.14e-05	0.00012	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTEN—thyroid cancer	9.99e-06	0.000105	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTGS2—thyroid cancer	9.78e-06	0.000103	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTEN—thyroid cancer	8.53e-06	8.99e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKT1—thyroid cancer	5.75e-06	6.06e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKT1—thyroid cancer	4.92e-06	5.18e-05	CbGpPWpGaD
